-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Reiterates Outperform on Fate Therapeutics, Maintains $7 Price Target

Benzinga·08/14/2026 13:10:01
Listen to the news
Wedbush analyst Martin Fan reiterates Fate Therapeutics (NASDAQ:FATE) with a Outperform and maintains $7 price target.